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Abstract
Myotonic dystrophy type 1 (DM1) and type 2
(DM2) are multisystemic disorders linked to
two different genetic loci and characterized by
several features including myotonia, muscle
weakness and atrophy, cardiac dysfunctions,
cataracts and insulin-resistance. In both
forms, expanded nucleotide sequences cause
the accumulation of mutant transcripts in the
nucleus deregulating the activity of some RNA-
binding proteins and providing an explanation
for the multisystemic phenotype of DM
patients. However this pathogenetic mecha-
nism does not explain some histopathological
features of DM skeletal muscle like muscle
atrophy. It has been observed that DM muscle
shares similarities with the ageing muscle,
where the progressive muscle weakness and
atrophy is accompanied by a lower regenera-
tive capacity possibly due to the failure in
satellite cells activation. The aim of our study
is to investigate if DM2 satellite cell derived
myoblasts exhibit a premature senescence as
reported for DM1 and if alterations in their
proliferation potential and differentiation
capabilities might contribute to some of the
histopathological features observed in DM2
muscles. Our results indicate that DM
myoblasts have lower proliferative capability
than control myoblasts and reach in vitro
senescence earlier than controls. Differentely
from DM1, the p16 pathway is not responsible
for the premature growth arrest observed in
DM2 myoblasts which stop dividing with
telomeres shorter than controls. During in
vitro senescence, a progressive decrease in
fusion index is observable in both DM and con-
trol myotubes with no significant differences
between groups. Moreover, myotubes obtained
from senescent myoblasts appear to be smaller
than those  from young myoblasts. Taken
together, our data indicate a possible role of
DM2 premature myoblast senescence in skele-
tal muscle histopathological alterations i.e.,
dystrophic changes and type 2 fibre atrophy.
Introduction
Myotonic dystrophies (DM) are autosomal
dominant multisystemic disorders character-
ized by a variety of multisystemic features
including myotonia, muscular dystrophy, car-
diac dysfunctions, cataracts and insulin-resis-
tance.1 Myotonic dystrophy type 1 (DM1) is the
most prevalent form of adult neuromuscular
disorder and is caused by an expanded (CTG)n
in the 3’ untranslated region of the Dystrophia
Myotonic Protein Kinase (DMPK) gene.2-4 The
second form of DM, myotonic dystrophy type 2
(DM2), is caused by the expansion of a
tetranucleotidic repeat (CCTG)n in the intron
1 of the CCHC-type zinc finger, nucleic acid-
binding protein (CNBP) gene.5,6 In both forms,
the mutant transcripts accumulate in nuclear
foci altering the function of several alternative
splicing regulators, which are necessary for
the physiological processing of mRNAs.7-10
These alterations lead to a spliceopathy i.e., an
aberrant alternative splicing of different genes
that explain different features of the DM mul-
tisystemic phenotype.11,12 However, at the
skeletal muscle level, still there is no mecha-
nistic explanation for the muscle weakness
and atrophy observed in DM patients or for the
muscle histopathological features characteris-
tic of this disease which includes fibre atro-
phy-hypertrophy, increased number of central
nuclei, and presence of fibres with nuclear
clumps.13-15
It has been obseved that in DM muscle tis-
sue there is decreased muscle regeneration in
response to the ongoing muscle loss and dys-
trophy1 thus it is possible that the blunted
repair response may result from impaired myo-
genesis in adult DM muscle. Interestingly, DM
muscle shares apparent similarities with the
ageing muscle where the progressive muscle
weakness and atrophy is accompanied by a
slower regenerative capacity.16-20 Satellite cells,
the muscle precursor cells, provide the poten-
tial for both pre and post-natal growth of skele-
tal muscles, and for its regeneration following
injury.21,22 In normal muscles, satellite cells are
quiescently located between the sarcolemma
and the basal lamina of mature myofibres; fol-
lowing injury they become activated and then
proliferate and fuse into myotubes to regener-
ate or repair muscle fibres.23,24 It is known that
the regenerative capacity of skeletal muscle
depends on the number of progenitor cells
which declines with age in humans and on
their activation, proliferation and differentia-
tion potential.25-27 The proliferative potential of
human satellite cells decreases during postna-
tal muscle growth due to the replicative senes-
cence.25,26 Replicative senescence may be
caused by progressive telomere shortening at
each cellular division or by additional path-
ways such as the p16 stress pathway, which
could also interfere with the proliferation
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capacity of human myoblasts by inducing pre-
mature senescence.28,29 It is therefore possible
that an early senescence of satellite cells could
affect both the regeneration process and the
maintenance of muscle mass, since the differ-
entiation program of senescent myogenic pre-
cursor cells would become defective due to
impaired myogenesis and/or the down-regula-
tion of the myogenic regulatory factors.
Indeed, Bigot et al. observed that senescent
myoblasts are still able to fuse and form
myotubes, yet significantly smaller and with a
significant reduction in the number of nuclei
per myotube and in the fusion index, com-
pared with those obtained from young
myoblasts.29 Such defects have been observed
in diseases involving repeated cycles of degen-
eration-regeneration, such as the Duchenne
muscular dystrophy (DMD), where satellite
cells display a defective phenotype related to
the exhaustion of proliferative capacity.30
Defective myoblasts have also been observed
from biopsies of patients suffering from other
neuromuscular disorders such as oculo-pha-
ryngeal muscular dystrophy, sporadic inclusion
body myositis and DM1.31-33 In a recent report,
it has been demonstrated that satellite cells
isolated from DM1 patients reached the prolif-
erative senescence when their mean telomere
lengths were longer than those observed in
passage-matched control cells indicating that
DM1 cells reach proliferative arrest prema-
turely, independently of telomere shortening.34
A premature growth arrest of satellite cells
from congenital DM1 patients carrying large
CTG expansions has also been observed, and
the p16 pathway appears to be responsible for
this phenomenon.35 As reported for adult DM1
myoblasts, these foetal myoblasts stop dividing
when their telomeres are significantly longer
than those of control cells.35 The early occur-
rence of senescence-related features in satel-
lite cell-derived myoblasts suggests that satel-
lite cells from DM1 patients have a reduced
regeneration capability, which would con-
tribute to the muscular dystrophic phenotype.
Recently, our group has shown that DM2
myoblasts at early culture passages, when they
proliferate at a similar rate as the controls,
already show senescence related features
mainly consisting in the early appearance of
cytological alterations and impairment of the
pre-mRNA maturation pathways.36 The aim of
our study is to elucidate if satellite cell derived
myoblasts obtained from skeletal muscle of
DM2 adult patients also exhibit a premature
senescence as reported for DM1 and if alter-
ations in their proliferation potential and dif-
ferentiation capabilities might contribute to
some of the clinical and histopathological fea-
tures observed in DM2 muscles. 
Materials and Methods
This study was authorized by the
Institutional Ethics Committee of the Local
Health Unit (ASL MI2, Melegnano, Milan,
Italy) and was conducted according to the prin-
ciples expressed in the Declaration of
Helsinki, the institutional regulation and
Italian laws and guidelines. Written informed
consent were obtained from the patients for all
blood samples and muscle biopsies used in
this study.Patients
Human muscle biopsies from biceps brachii
muscle were taken under sterile conditions
from DM1 (n=3) and DM2 (n=4) patients
enrolled in Ilalian DM Registry and from age
matched subjects with no sign of neuromuscu-
lar disease (n=4) used as controls. The diag-
nosis of DM was based upon the clinical diag-
nostic criteria set by the International
Consortium for Myotonic Dystrophy.37 DM2
diagnosis was performed by fluorescence in
situ hybridization on muscle frozen sections
using a (CAGG)5 probe as previously reported
by Cardani et al.38 to verify the presence of
ribonuclear inclusions. DM1 and DM2 geno-
typing were performed on genomic DNA
extracted from peripheral blood leukocytes as
previously described.39-41
Muscle histopathology andimmunohistochemistry
Biceps brachii biopsies were fresh-frozen in
isopentane cooled in liquid nitrogen.
Histopathological analysis was performed on
serial sections (8 µm) processed for routine
histological and histochemical stainings. A
standard myofibrillar ATPase staining protocol
was used after preincubation at pH 4.3, 4.6,
and 10.4.42 Immunohistochemical staining was
performed on serial sections (6 μm) air-dried
and rehydrated in phosphate buffer pH 7.4
(PBS). Non-specific binding sites were blocked
with normal goat serum (NGS; Dako, Glostrup,
Denmark) at a dilution 1:20 in PBS containing
2% bovine serum albumin (BSA; Sigma-
Aldrich, St. Louis, MO, USA) for 20 min at room
temperature. Sections were then incubated for
1 h at room temperature with mouse mono-
clonal primary antibodies against two different
myosin heavy chain (MHC): MHCfast, diluited
1:400 in PBS+2%BSA (Sigma-Aldrich);
MHCslow, diluited 1:400 in PBS+2%BSA
(Sigma-Aldrich). After washing in PBS 3 times
for 5 min (3x5 min), sections were incubated
for 1 h at room temperature with goat anti-
mouse biotinylated secondary antibody diluted
1:300 in PBS+2%BSA. After washing in PBS
3x5 min, sections were incubated for 30 min
with Vectastain ABC complex (Vector
Laboratories, Burlingame, CA, USA) and then
with 3,3’-Diaminobenzidine (DAB) and hydro-
gen peroxide for 20 min. Nuclei were counter-
stained with Mayer’s hematoxylin.
Quantitative evaluation of fiber diameter was
made as described previously by Vihola et al.13
with Scion Image (Scion Corporation,
Frederick, MD, USA) on images taken with a
light microscope (1600x, original magnifica-
tion). The size of muscle fibers was assessed
by measuring the smallest fiber diameter and
all data were elaborated using Microcal Origin
(Microcal Software Inc., Northampton, MA,
USA). The metahistograms were normalized to
normal mean diameter for men and women.
Relative atrophy and hypertrophy factors were
also calculated.Primary skeletal muscle cell cultures
The human satellite cells were isolated from
muscle biopsies as reported by Cardani et al.43
Myoblasts were grown in HAM’s F10 medium
(Sigma-Aldrich) supplemented with 15% FBS
(Euroclone), 0.5 mg/mL albumin from bovine
serum (BSA, Sigma-Aldrich), 0.5 mg/mL fetuin
(Sigma-Aldrich), 0.39 μg/mL dexamethasone,
10 ng/mL epidermal growth factor, 0.05 mg/mL
insulin, 3 mg/mL glucose, 100 U/mL penicillin
and 100 μg/mL streptomycin (proliferative
medium). For this study, cells from DM and
control patients were plated at a density of
85,000 cells per 60 mm dishes or 50,000 cells
per 35 mm dishes. Myogenic purity was evalu-
ated by immunofluorescence using desmin as
marker (see below). The percentage of desmin
positive myoblasts was calculated as the num-
ber of positive cells vs the total number of cells
observed. All starting cell populations used in
this study had a myogenic purity higher than
80%. Moreover, the myogenic purity was mon-
itored every 5 passages (7 days per passage for
a total of 35 days) until senescence was
reached. At least 100 cells were counted in at
least 10 different optical fields randomly cho-
sen.Proliferative capacity and senes-cence
Cells from DM patients and controls were
plated in triplicate at the density 50,000 per 
35 mm dishes and, after 7 days, were
trypsinized, counted with trypan blue and then
replated at the same density (I passage; early
stage). At each passage, every 7 days, the pro-
liferative capacity was evaluated as mean pop-
ulation doubling (MPD) using the formula log
(N/n)/log2 where N is the number of cells
counted and n is the number of cells initially
plated. Cultures were considered to be in
senescence when cells have arrested their
growth for 3 consecutive passages (late stage).
As biomarker for replicative senescence, SA-β-
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gal, a β-galactosidase activity detectable in cul-
tured cells undergoing replicative senescence
but absent from proliferating cells, was evalu-
ated according to Dimri et al.44 on myoblast at
early and late stages of proliferation.
Quantification of SA-βGal positive cells was
done by counting blue stained cells in 5 ran-
domly selected fields and expressing the per-
centage of positive cells respective to the total
number of cells visualized in each field.Differentiative capacity
Myoblasts at early and late stages were plat-
ed at a high density in 35 mm dishes and,
when they reached 80% of confluence, prolifer-
ative medium was replaced by differentiative
medium (DMEM/High Glucose supplemented
with 7% FBS, in presence of 100 U/mL peni-
cillin, 100 μg/mL streptomycin and 0.01 mg/mL
insulin) to allow myoblasts fusion. This condi-
tion of plating at high density prior to inducing
differentiation was chosen in order to elimi-
nate any bias in the quantification of fusion,
which could be decreased by the poor migra-
tion of senescent cells.  After 5 days in differ-
entiative medium (T5), myotubes were ana-
lyzed in term of protein expression (MHC-fast
myosin and myogenin, a myogenic factor
involved in myoblast differentiation; see
below) and fusion index to evaluate myoblasts
differentiative capacity. Fusion index was
determined as number of nuclei in multinucle-
ated myotubes expressed as a percentage of
the total number of nuclei. At least 100 nuclei
were counted in at least 10 different optical
fields randomly chosen.Immunofluorescence
Immunofluorescence has been performed
on proliferating myoblasts at early stage, on
senescent myoblasts at late stage and on
myotubes obtained from myoblasts at early and
late stages.  Myoblast and myotube (T5) cul-
tures were fixed in 4% paraformaldehyde for
15 min at 4°C. After fixation, cells were washed
several times in PBS and then permeabilized
in 0.4% Triton X-100 in PBS for 5 min. After
washing in PBS, non-specific binding sites
were blocked with NGS (Dako-Cytomation) at
a dilution 1:20 in PBS+2% BSA for 20 min at
room temperature. Myoblast and myotubes
were then incubated respectively with a pri-
mary antibody mouse monoclonal anti-desmin
(CD33, Dako, 1:100 in PBS+2%BSA) and a
mouse monoclonal anti MHC-fast (Sigma-
Aldrich, 1:600 in PBS+2%BSA) for 1 h at room
temperature. After washing in PBS 3x5 min,
cells were incubated for 1 h at room tempera-
ture with secondary antibodies (goat anti
mouse Alexa 488-labeled; Molecular Probes,
Eugene, OR, USA; 1:400 in PBS+2%BSA). After
washing in PBS 3x5 min, nuclei were stained
with 165 nM 4,6-diamidino-2-phenylindole
(DAPI). Cells were finally mounted with
Mowiol and examined using a fluorescence
microscope (LEICA FW4000).Western blot analysis  
During the in vitro ageing, the expression
of different proteins involved in proliferation
and/or in differentiation was analyzed by west-
ern blot (WB) on myoblasts or on myotubes
(T5) protein extracts. WB analyses were per-
formed on proliferating (early stage) and non-
proliferating (late stage) myoblasts and on
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Figure 1. Cross-sections of skeletal muscle from DM1 (A) and DM2 (B) patient after immunostaining for fast myosin. Note the pres-
ence of type 1 (white arrowhead) and type 2 (black arrowhead) atrophic fibers in DM1 section (A), while in DM2 section (B) type 2
fibre atrophy (black arrowhead) is evident. Black arrows indicate fast positive nuclear clumps. Relative hypertrophy factor (HF) and
atrophy factor (AF) of each DM1 and DM2 patients (C) and mean values ± standard error of the mean (SEM) of HF and AF for each
patient group (D). The results are based on the morphometric analysis of sections immunostained for MHC fast or slow myosin. 
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myotubes obtained from myoblasts at early and
late stage.  Whole cell extracts were prepared
by the addition to the plates of lysis buffer [50
mM Tris–HCl, pH 7.4 (TBS), 200 mM NaCl, 1%
NP-40, 1 mM phenylmethylsulfonyl fluoride,
0.1% SDS, 0.5% sodium deoxycholate, 10 mM
b-glycerophosphate, 10 mM sodium fluoride, 1
mM sodium vanadate, Protease inhibitor cock-
tail (Sigma Aldrich)] and rubbed with a cell
scraper. After incubating on ice for 15 min,
samples were centrifuged at 5700g for 15 min
at 4°C, and supernatant was collected and
stored at -80°C. Pellets were suspended in 50
mM TBS with 5% SDS and stored at -80°C.
Protein concentration in each sample was
determined by using BCA assay kit (Pierce,
Rockford, IL, USA). Eight μg of protein for each
sample was loaded per lane and elec-
trophoresed on 8% or 15% sodium dodecyl sul-
fate-polyacrylamide gels, and than transferred
to nitrocellulose membranes (Bio-Rad
Laboratories). After blocking non specific sites
in TBS containing 5% BSA for 30 min at 42°C,
membranes were incubated overnight at 4°C
with different primary antibodies diluted in
TBS+5%BSA+0.1%Tween20 for mouse mono-
clonal antibodies, and in TBS+5%BSA+
0.3%Tween20 for rabbit polyclonal antibodies.
The expression of desmin (1:500; Clone D33;
Dako-Cytomation), MyoD (1 μg/mL; Clone
5.2F; Sigma-Aldrich), p16 (1:200; Clone H-156;
Santa Cruz Biotechnology, Santa Cruz, CA,
USA) and PCNA (1:5000; Clone PC10; Dako-
Cytomation) was analyzed in myoblast cul-
tures, while MHCf (1:5000; Sigma-Aldrich) and
myogenin (1 μg/mL; Clone F12B; Sigma-
Aldrich) were analyzed in myotubes cultures.
After several washes in TBS+0.2%Tween20,
membranes were incubated with horseradish
peroxidase conjugated goat anti-mouse or
anti-rabbit secondary antibodies diluted
respectively 1:5000 and 1:10,000 in TBS+5%
BSA+0.2%Tween20 (Jackson Immuno Research
Laboratories, West Grove, PA, USA). Membranes
were washed and immune complexes were
detected using the ECL detection system
(Amersham Pharmacia Biotech, Piscataway,
NJ, USA).  Blots were performed in triplicate.DNA extraction and telomerelength analysis 
Genomic DNA has been extracted from
1x106 DM1 (n=2), DM2 (n=4) and control
(n=3) myoblasts at early and late stages with
FlexiGene kit (QIAGEN, Hilden, Germany), fol-
lowing the manufacture’s instructions. The
quantification of telomere lengths has been
assessed through Southern blot analysis of ter-
minal restriction fragments (TRF) using the
TAGGG Telomere Length Assay (Roche).
Briefly, 2 μg of genomic DNA from each sample
were digested with HinfI and RsaI enzymes,
digested fragments were resolved by gel elec-
trophoresis in a 0.8% agarose gel and trans-
ferred onto a nylon membrane. The blotted
DNA fragments were hybridized to a digoxi-
genin (DIG)-labeled (TTAGGG)4 probe and
incubated with a anti DIG-specific antibody
covalently coupled to alkaline-phosphate.
Metabolized CDP-Star substrate is then detect-
ed by chemiluminescence indicating the loca-
tion of the TRF on the blot. The average TRF
length was determined by comparing the loca-
tion of the TRF on the blot relative to a molec-
ular weight standard. The TRF signal has been
scanned and digitalized by STORM 860
(Molecular Dynamics, Sunnyvale, CA, USA)
and ImageQuant software. Mean TRF lengths
have been calculated for each sample on three
independent gels, as reported previously by
Kimura et al.45 The number of cell division
being known, the shortening velocity of telom-
eres has been determined, and it has been cal-
culated whether in DM cells the telomere loss
is higher than in controls.Statistical analysis
To determine significance between two
groups, comparisons were made using an
unpaired Student’s t-test. The groups were
considered statistically different at P<0.05. 
ResultsPatients and skeletal musclehistopathology
This study was performed on DM1 and DM2
age-matched patients compared to subjects
with no sign of neuromuscular disease used as
controls. Although the number of patients ana-
lyzed in this study was small, DM1 and DM2
groups were homogeneous: the DM1 cohort
was represented by 3 classical adult patients
mildly affected with a range of CTG repeat
expansion of 361.6±102.8 (E2) and the MIRS
was 3-4, the DM2 cohort was represented by 4
patients with classical PROMM phenotype and
fluctuating myotonia, except for patient #3
(Table 1).
Analysis of muscle sections immunostained
for MHC fast or slow myosin allows us to detect
and measure fibers smaller than 5 µm, includ-
ing all nuclear clump fibers which are recog-
nizable by the presence of a thin rim of
immunoreaction around the nuclei (Figure 1
A,B). All patients used in this study show an
increase of fibre atrophy. In particular, an
increase of both type 1 and type 2 fiber atrophy
is present in DM1 patients and a prevalent type
2 fibre atrophy is evident in DM2 patients.
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Table 1. Clinical data of patients analyzed in this study.
Patient          Sex                     Age at onset             Age at biopsy     CTG expansion                 Myotonia                 MIRS°             MRC#
CTR-1                     F                                           -                                          43                                   -                                     Not present                           -                           -
CTR-2                    M                                           -                                          44                                   -                                     Not present                           -                           -
CTR-3                    M                                           -                                          48                                   -                                     Not present                           -                           -
CTR-4                     F                                           -                                          48                                   -                                     Not present                           -                           -
DM1-1                   M                                         38                                         39                                370                                            ±                                    3                      128.35
DM1-2                    F                                          35                                         45                                460                                           ++                                  4                      128.35
DM1-3                   M                                         39                                         47                                255                                            +                                    4                      105.36
DM2-1                    F                                          35                                         51                                   -                                               +                                    -                       118.70
DM2-2                    F                                          35                                         53                                   -                                               ±                                    -                       132.99
DM2-3                    F                                          19                                         45                                   -                                             ++                                  -                       128.68
DM2-4                    F                                          54                                         59                                   -                                               +                                    -                       109.68
°Muscle Impairment Rating Scale, stage of the disease for myotonic dystrophy type 1 (DM1) patients.53 #Medical Research Council, scale for muscle strength; scale (0-5 grade) on 15 muscles at both
sides in the upper and lower limbs for a total of 150 maximum score. CTR, control; DM1, myotonic dystrophy type 1; DM2, myotonic dystrophy type 2; F, female; M, male. 
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Figure 2. A) Representative western blot analysis of MyoD expression in myoblasts at early (e) and late  (l) passages of proliferative lifes-
pan obtained from biceps brachii muscle samples from healthy (CTR), DM1 and DM2 patients; density of the bands has been normal-
ized to β-tubulin expression used as internal control. B) Histograms representing mean values of MyoD protein expression analysed by
densitometry of CTR (n=4), DM1 (n=3) and DM2 (n=4) patients; scale bars are for SEM. MyoD expression is similar in young and
senescent cells indicating that the myogenic purity persists to be high throughout the experiment. C) Lifespan plots of control and DM
myoblasts. D) Mean of max number of divisions of CTR (n=4), DM1 (n=3) and DM2 (n=4) patients; scale bars represent SEM; the
average proliferative lifespan of the DM myoblasts is reduced as compared to that of control cells. E) Representative western blot analy-
ses of PCNA in the early (e) and late (l) stages of myoblast proliferative lifespan; the results have been normalized to the expression of
β-tubulin. F) Histograms representing mean values of PCNA protein expression analyzed by densitometry of CTR (n=4), DM1 (n=3)
and DM2 (n=4) patients; scale bars represent SEM; levels of PCNA are significantly decreased in both DM and control senescent cells
compared to young cells. *P<0.05, **P<0.01.
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Hypertrophic type 1 and type 2 fibers were also
present in DM patients (Figure 1C). The eval-
uation of atrophy (AF) and hypertrophy (HF)
factors for each patient group are reported in
Figure 1D.Myoblast cultures and proliferativecapacity
The myogenic purity of cell preparations
was evaluated from the percentage of cells
expressing desmin. Immunofluorescence
assay revealed that the cell preparations used
in this study were quite similar in terms of the
desmin expression. The myogenic purity was
around 75-80% throughout the experimental
procedures (data not shown). Also MyoD pro-
tein expression indicated that the myogenic
purity remained similar in the early and late
stages both in DM and control cultures (Figure
2 A,B). 
The in vitro proliferative capacity of
myoblasts obtained from skeletal muscle biop-
sies of 3 DM1 and 4 DM2 patients was com-
pared to that of myoblasts obtained from 4 age-
matched unaffected individuals used as con-
trols. As shown in Figure 2C, an interindivid-
ual variability was evident in both DM1 and
DM2 patient group, however the average pro-
liferative lifespan of the DM1 and DM2
myoblasts was reduced by 50% and 36%
respectively as compared to that observed in
control cells. Moreover, DM1 (9 passages) and
DM2 (10 passages) myoblasts stopped dividing
earlier compared with control cultures (15 pas-
sages) (Figure 2C). Myoblasts from DM1 and
DM2 patients showed a clear reduction of the
maximum number of divisions compared to
those observed in controls cells (Figure 2D).
Analysis of PCNA expression showed a signifi-
cant reduction of protein expression in the late
passages compared to the early stages both in
DM and control cells (Figure 2E,F). The
expression of PCNA in the late passages indi-
cated that the majority of DM and control cells
were arrested in G1 phase of the cell cycle.Senescence analysis
To evaluate if a mechanism similar to
senescence was responsible for the early pro-
liferative growth arrest of DM myoblasts, we
analyzed biomarkers usually observed in
senescent cells. At early passages DM and con-
trol cells were actively dividing with rare or no
senescent cells being detected but as the cells
reached their late passage, the number of
senescent cells positive for SA-β gal increased
dramatically in both DM and control cells
(Figure 3). Moreover, DM and control
myoblasts at the late stages of proliferation
showed a flattened morphology with an
enlarged cytoplasm and extended cytosolic
processes, a morphology reminiscent of that
observed when myoblasts reach a senescent
state (Figure 4).
We examined the expression of p16 protein
at the beginning and at the end of DM lifespan
to verify if this mechanism was also involved
in the premature proliferative arrest observed
in DM2 myoblasts in vitro. Our analysis indi-
cate that p16 was overexpressed in DM1 cells
both at the early and late stages compared to
controls, while p16 protein expression
appeared to be similar in DM2 and control
myoblasts at both stages analyzed (Figure 5
A,B). Critically short telomeres trigger loss of
cell viability in tissues, which has been related
to alteration of tissue function and loss of
regeneration tissue capabilities. Since it has
been observed that DM1 myoblasts stopped
dividing prematurely independently of telom-
ere shortening,34,35 we have analyzed telomere
loss induced by in vitro aging in satellite-cell-
derived myoblasts, isolated from muscles of
DM1 (n=2), DM2 (n=4) patients and from
age-matched control subjects (n=3). As shown
in Figure 5C, satellite cells isolated from DM1
patients stopped growing prematurely with
telomeres longer than controls (respectively
11.4±1.1 Kb and 9.5±0.3 Kb), differently from
what observed in DM2 myoblasts which stop
dividing with a median telomere length of
8.3±1.7 Kb even if a wide variability in mean
TRF length can be observed in DM samples. It
should be noted that the two DM2 cultures  (#2
and #3, Figure 2C) showing the most prema-
ture growth arrest also showed the shortest
telomere length at the early stages probably
indicating an excessive proliferation in vivo
before their isolation (data not shown).
Moreover these two DM2 patients also show
the highest values of atrophy factor in vivo
(Figure 1C). As shown in Figure 5D, DM2
satellite cells has a clear two-fold decrease in
the amount of telomeric DNA at every cell pas-
sage compared to controls whereas in DM1
cells the mean bp loss per division is 30% lower
than controls. Differentiative capacity
Myoblasts at early and late stages of prolifer-
ation were induced to fuse into myotubes dur-
ing 5 days of differentiation (T5) in order to
evaluate their differentiative capacity.
Although the senescent cells were still able to
form myotubes, they appeared to be signifi-
cantly smaller than those formed by the young
cells, which also formed branched myotubes
not observable in senescent cultures (Figure 6
A-F). As observed in Figure 6G, a significant
reduction in fusion index is observable both in
DM and control myoblasts which has reached a
proliferative arrest compared to proliferating
myoblasts. This reduction appears to be more
evident in senescent myoblasts from DM1
patients who also show higher value of atrophy
factor compared to DM2. Moreover, the expres-
sion of myogenin appeared to be decreased
both in DM and control myotubes obtained
from non-proliferating myoblasts as compared
to those obtained from proliferating myoblasts
(Figure 6 H,I). 
Discussion
Many symptoms of adult form of DM1 and
DM2, such as muscle weakness and wasting,
cataracts, and cardiac arrhythmias, are remi-
niscent to normal aging. Recent data on dys-
trophic skeletal muscle myonuclei have
demonstrated alterations of mRNA pathways
similar to those observed during aging.19,46-48
Increasing evidence has demonstrated that in
age-related myopathies, such as sarcopenia
and myotonic dystrophy, the progressive mus-
cle weakness and atrophy are characterized by
impaired muscle regeneration due to satellite
cells premature senescence that limits their
proliferative potential.1,35,49,50 In DM1 muscles
the number of satellite cells is increased com-
pared to muscles from non-affected individu-
als; however, DM1 cells do not seem to be able
to counteract  the progressive muscle atrophy
due to a reduced proliferative capacity trig-
gered by a mechanism of premature growth
arrest.34
It is known that primary DM myoblasts do
not show evident morphological abnormalities
and are capable of normally differentiat-
ing;43,51,52 however, we have recently observed
that DM2 myoblasts are characterized by
senescence related features mainly consisting
in the early appearance of cytological alter-
ations and impairment of the pre-mRNA matu-
ration pathways.36 To further investigate DM2
myoblasts aging, we have analyzed if cultured
myoblasts from DM2 patients differ from
myoblasts of age-matched DM1 and normal
individuals  in terms of cell proliferation, mor-
phology, differentiation and senescence during
in vitro aging and if alterations in their prolif-
eration potential and differentiation capabili-
ties might contribute to some of the clinical
and histopathological features observed in
DM2 muscles.
Our results seem to indicate that DM1 and
DM2 myoblasts are characterized by a prema-
ture proliferative growth arrest compared to
healthy myoblasts. Moreover, a mechanism
similar to senescence appear is to be responsi-
ble for the early proliferative growth arrest
because DM cells expressed biomarkers usual-
ly observed in senescent cells much earlier in
their replicative lifespan as compared with
age-matched control cultures. These data sug-
gest that the in vivo regenerative capacity of
DM satellite cells might be constitutively
impaired. Furthermore, while the p16 pathway
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Figure 3. Representative images of CTR (A,B), DM1 (C,D) and DM2 (E,F) myoblasts stained for the senescence-associated β-galactosi-
dase (SA-βGal) activity. At the proliferative (early) stages, very few cells were positive (A,C,E). At the high cell passage (late stages),
myoblasts appear large, with the characteristic cytoplasmic blue staining typical of senescence (B,D,F). G) Quantification of the
amount of SA-βGal positive cells shows a dramatic increase in the percentage of positive cells at the late stages; scale bars represent
SEM.
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Figure 4. Representative images of CTR (A,B), DM1 (C,D) and DM2 (E,F) myoblasts immunostained for the myogenic marker,
desmin.  Both DM and control myoblasts at early stages of proliferation were relatively small and elongated (A,C,E), while at the late
stages of proliferation they showed a flattened morphology with enlarged cytoplasm and extended cytosolic processes (B,D,F). Nuclei
have been visualized with DAPI (blue). 
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Figure 5. DM premature senescence pathway. A) Representative western blot analyses of p16 in the early (e) and late (l) stages of
myoblast proliferative lifespan; the results have been normalized to the expression of β-tubulin. B) Histograms representing mean val-
ues of p16 protein expression analysed by densitometry in healthy (CTR; n=4), DM1 (n=3) and DM2 (n=4) patients; at both stages
analyzed, p16 was more expressed in DM1 cells as compared to the controls while the expression was similar in DM2 and control
myoblasts; scale bars represent SEM. C) Mean length of telomeric restriction fragments (TRF) measured on DM2 (n=4) and control
(n=4) myoblasts at proliferative and senescent stage; senescent DM2 cells had shorter telomeres than the proliferating cells (*P<0.05);
scale bars represent SEM. D) Mean length (in bps) of telomeric DNA lost per division in control and DM2 myoblasts; DM2 cells lost
more bps per division than control cells; scale bars represent SEM. 
appear to be responsible for the premature
growth arrest in DM1 probably in response to a
CTG-related stress,35 our results suggest that
this mechanism is not responsible for the pro-
liferative arrest observed in DM2 myoblasts.
On the contrary, differently from what
observed in DM1 myoblasts and reported in lit-
erature,33-35 DM2 myoblasts stop dividing with
telomeres shorter than controls suggesting
that the signaling involved in premature
senescence depend on a telomere-driven path-
way. CCTG expansion might interfere with the
telomere homeostasis in DM2 cells, yet the
mechanism causing an accelerated telomere
shortening has to be clarified. Critically short
telomeres trigger loss of cell viability in tis-
sues, which has been related to alteration of
tissue function and loss of regeneration tissue
capabilities. Each time a satellite cell divides,
its DNA loses a small portion of this telomeric
sequence;53 once a critical length is reached,
the cell becomes senescent and can no longer
play a role in regeneration. Telomere length is
an important predictive biomarker indicative
for the regenerative capacity of human satel-
lite cells as shown in Duchenne muscular dys-
trophy in which a telomere shortening after
continuous cycles of degeneration and regen-
eration has been reported.30 Hence, it appears
that CTG and CCTG expansions trigger in vitro
a mechanism of myoblast premature senes-
cence through two different pathways, which
could explain the different histological alter-
ations observed between DM1 and DM2 skele-
tal muscle as for example the selective type 2
fibre atrophy present in DM2 muscle. However,
further studies will be necessary to better
understand how different senescence mecha-
nisms involved in DM1 and DM2 myoblasts
could lead to the selective involvement of type
1 or type 2 fibers in DM1 and DM2 respectively.
As previously reported,29,54 our results indicate
that replicative senescence deregulates the
myogenic programme resulting in impaired
myogenesis. A decrease of the expression of
myogenin, a myogenic factor involved in
myoblast differentiation, is observable in
myotubes obtained from senescent myoblasts
as compared to those observed from proliferat-
ing myoblasts. Moreover, even though the
senescent myoblasts are still able to fuse, a
significant reduction in the fusion index has
been observed when compared with young
cells. It should be noted that the reduction in
fusion index appear to be more evident in
senescent myoblasts obtained from DM1
patients indicating that myoblasts deficiency
could be responsible of the more severe mus-
cle histopathology observed in DM1 compared
to DM2. The reduced differentiating capacity is
due to defect in differentiation and/or fusion
properties of the senescent myoblasts and not
to a decrease in the motility of senescent cells,
since differentiation in senescent cultures was
induced in myoblasts seeded at very high den-
sity. Thus, the histopathological defects
observed in DM muscle such as fibre atrophy
and nuclear clumps, could be due at least in
part to the inability of premature aged
myoblasts to generate myotubes able to pro-
duce mature skeletal muscle fibers or to fuse
with existing fibers and prevent them from
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Figure 6. Differentiation capability of young and senescent myoblasts. A-F) Fast myosin immunofluorescence (green) of control (A,B),
DM1 (C,D) and DM2 (E,F) myotubes from myoblasts at early and late stages of their proliferative lifespan, after 5 days of differenti-
ation (T5). Nuclei have been visualized with DAPI (blue). Young myoblasts generate well-differentiated and cross-striated (C,E)
myotubes larger than those formed by the senescent cells. G) Fusion index, i.e. the number of nuclei incorporated into myotubes as a
percentage of the total number of nuclei, has been calculated in young and senescent myoblasts after 5 days of differentiation; a signif-
icant reduction of fusion index is observable in both DM and control myotubes obtained from senescent cells (*P<0.05, **P<0.01). H)
Histograms represents mean values of myogenin protein expression analysed by densitometry of control (n=4), DM1 (n=3) and DM2
(n=4) patients; a reduced myogenin expression is observed in myotubes from senescent cells as compared to those obtained from young
cells; scale bars represent SEM. I) Representative western blot analyses of myogenin in myotubes obtained from myoblasts at the early
(e) and late (l) stages of their proliferative lifespan; the results have been normalized to the expression of β-tubulin. 
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atrophy. Although this study has been carried
out on a limited number of cases, it seems
indicate that, as in DM1 patients, myoblast
premature senescence could explain the skele-
tal muscle wasting observed in patients affect-
ed by DM2.  
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